Seres Therapeutics (MCRB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MCRB · Stock Price

USD 7.72-0.16 (-2.03%)

Market Cap: $73.8M

Historical price data

Market Cap: $73.8MPipeline: 9 drugs (2 Phase 3)Founded: 2010Employees: 100-250HQ: Cambridge, United States

Sector Ranking#4 in Microbiome Therapeutics

Overview

Seres Therapeutics is a trailblazer in the microbiome field, with a mission to transform patient lives by restoring microbiome health. Its landmark achievement is the FDA approval and commercialization of VOWST™ for recurrent C. difficile infection, validating its platform and establishing a first-mover advantage. The company's strategy involves leveraging this platform to expand into larger gastrointestinal and immunology indications, while navigating the challenges of commercial execution, pipeline development, and financial sustainability.

Infectious DiseaseGastroenterologyImmunology

Technology Platform

Proprietary platform for discovering and manufacturing defined consortia of purified bacterial spores, designed to survive oral administration and restore a healthy microbiome.

Pipeline

9

9 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
SER-109 + Placebo	Clostridium Difficile Infection	Phase 3
SER-109	Clostridioides Difficile Infection	Phase 3
SER-109 + Placebo	Clostridium Difficile	Phase 2
Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatm...	Ulcerative Colitis	Phase 2
Placebo for antibiotic + Vancomycin pretreatment + Nivolumab...	Metastatic Melanoma	Phase 1

Funding History

4

Total raised:$267.5M

PIPE$75MUndisclosedSep 15, 2020

IPO$134MUndisclosedJun 26, 2015

Series B$48MFlagship PioneeringJun 15, 2014

Series A$10.5MFlagship PioneeringJun 15, 2012

Opportunities

The commercial launch of VOWST™ establishes a revenue base in the rCDI market.

The platform has potential for expansion into significantly larger markets like ulcerative colitis and high-need areas like preventing infections in immunocompromised patients, supported by orphan drug designations.

Risk Factors

Key risks include commercial execution challenges for VOWST™ against competition, clinical failure of pipeline candidates (as seen with SER-287), ongoing financial losses requiring additional capital, and the complex manufacturing of live biologic products.

Competitive Landscape

Seres competes directly with Ferring's Rebyota in the approved rCDI market and faces numerous biotech and pharma companies developing live biotherapeutics for gastrointestinal and immunology indications. Its first-mover oral approval and manufacturing platform are key differentiators.